Spectrum of HIV lymphoma 2009

Current Opinion in Hematology

Volumn 17, Issue 4, 2010, Pages 362-367

  Gucalp, Ayca ^a   Noy, Ariela ^b  

^a Department of Medicine ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AIDS; B cell large cell lymphoma; HIV; lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; RITUXIMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; VIREMIA; COMPLICATION; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIMODALITY CANCER THERAPY; PROCEDURES; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; HIV; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; STEM CELL TRANSPLANTATION; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77955681258     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328338f6b6     Document Type: Review

References (36)

1. Akanmu AS. AIDS-associated malignancies. Afr J Med Med Sci 2006; 35 (Suppl):57-70.
2. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511.
3. Gerard L, Galicier L, Boulnger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introductin of highly active antiretroviral therapy. AIDS 2003; 17:81-87.
4. Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645-650.
5. Tirelli U, Franceschi S, Carbone A. Malignant tumours in patients with HIV infection. BMJ 1994; 308:1148-1153.
6. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998; 16:3601-3606.
7. Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.AIDS 2009; 23:2029-2037.
8. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14:1065-1074.
9. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963.
10. Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94:875-880.
11. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79-87.
12. Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic pre-dictors of AIDS-related non-Hodgkin lymphoma in the highly active antire troviral therapy era. J Acquir Immune Defic Syndr 2009 [Epub ahead of print].
13. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
14. Breen EC, Epeldegui M, Boscardin WJ, et al. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lympho ma. AIDS 2005; 19:1711-1712.
15. MoirS, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245.
16. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 10:773-779.
17. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
18. Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762-1769.
19. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009; 27:5573-5579.
20. Nyman H, Adde M, Karjalainen-Lindsberg M, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109:4930-4935.
21. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochem-ical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009; 100:1842-1847.
22. Chadburn A, Chiu A, Lee JY, etal. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009; 27:5039-5048.
23. Lu P, Yang C, Guasparri I, et al. Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. Leukemia 2009; 23:807-810.
24. Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008; 22:1755-1766.
25. Capello D, Scandurra M, Poretti G, et al. Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol 2010; 148:245-255.
26. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and postgerminal center biomarkers. J Clin Oncol 2008; 26:2717-2724.
27. Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood 2006; 107:3014-3015.
28. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543.
29. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123-4128.
30. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated, B-cell non-Hodgkin's lymphoma. Blood 2009 [Epub ahead of print].
31. Balsalobre P, Diez-Martn JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27:2192-2198.
32. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114:1306-1313.
33. Diez-Martin JL, Balsalobre P, Re A, etal. Comparable survival between HIV+ and HIV\non-Hodgkin and Hodgkin lymphoma patients undergoing auto-logous peripheral blood stem cell transplantation. Blood 2009; 113:6011-6014.
34. Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Trans plant 2008; 14:601-602.
35. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
36. Mani D, Dorer RK, Aboulafia DM. Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma 2009; 9:316-319.